BioSpace News Archive

Vivos management to present at 7:00 am EDT on September 13, 2021

Freespira, Inc. today announced findings from a study in the September issue of the Journal of Applied Psychophysiology and Biofeedback demonstrating that PTSD severity can be significantly reduced with its first-of-its-kind treatment.

Bio-Thera Solutions Announces Commercialization and License Agreement for BAT1706, a Proposed Biosimilar Referencing Avastin ® (Bevacizumab)

Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced it will host a virtual R&D Day for analysts and investors on Wednesday, September 15, 2021 at 12:00 p.m. ET.

Selecta Biosciences, Inc. (NASDAQ: SELB), and Cyrus Biotechnology, Inc., today announced a protein engineering collaboration combining Selecta’s ImmTOR platform with Cyrus’ ability to radically redesign protein therapeutics.

Ensysce Biosciences, Inc. announced that it has enrolled the first cohort of subjects in a clinical study PF614-102 entitled “A Phase 1b, Randomized, 2-Part Single-Center Study to Evaluate the Pharmacokinetics and Safety of Multiple-Ascending Oral Doses of PF614 and the Food Effect and Bioavailability/Bioequivalence of Single Oral Doses of PF614 Relative to OxyContin in Healthy Adult Subjects.”

HiberCell, a clinical stage biotechnology company developing therapeutics to treat cancer relapse and metastasis, announced that the U.S. Food and Drug Administration has granted the company Fast Track designation for HC-5404-FU, an orally administered PERK inhibitor for patients with solid tumors.

VYNE Therapeutics Inc. announced that David Domzalski, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference to be held virtually from September 13th - 15th.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced the appointment of Mel Hayes as Chief Commercial Officer, effective September 7, 2021.

Calithera Biosciences, Inc., a clinical stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, announced that it will present a trial in progress poster of the Phase 2 study of telaglenastat at the International Association for the Study of Lung Cancer 2021 World Conference on Lung Cancer.